Cardiol Therapeutics (CRDL) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Voyager Therapeutics (VYGR) over the past year, gaining 24.5% versus a loss of 47.8%. Over five years, VYGR leads with a -39.8% price change compared with -66.4% for CRDL. Cardiol Therapeutics is the larger company by market cap ($160.4 million vs $152.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | VYGR |
|---|---|---|
| Share price | $1.32 | $2.47 |
| Market cap | $160.40M | $152.20M |
| 1-day change | +0.76% | +0.41% |
| YTD return | +38.36% | -37.15% |
| 1-year return | +24.53% | -47.78% |
| 5-year return | -66.41% | -39.76% |
| EPS (TTM) | $-0.25 | $-1.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $5.55 |
| 52-week low | $0.88 | $2.39 |
| Distance from 52-week high | -43.59% | -55.50% |
| Average volume | 1.39M | 563.34K |
| Shares outstanding | 121.51M | 61.62M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed VYGR by 72.3 percentage points over the past year.
CRDL vs VYGR FAQ
Which is bigger, Cardiol Therapeutics or Voyager Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $160.40M compared with $152.20M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, CRDL or VYGR?
CRDL returned +24.53% over the past 12 months, compared with -47.78% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.